Centers for Disease Control and Prevention, National Center for HIV/Hepatitis/STD/TB Prevention, Division of Viral Hepatitis, Atlanta, GA 30333, USA.
Virus Res. 2011 Oct;161(1):93-100. doi: 10.1016/j.virusres.2011.05.008. Epub 2011 May 18.
Hepatitis E virus (HEV) causes large epidemics of enterically transmitted acute hepatitis and accounts for a majority of sporadic acute hepatitis in endemic countries. Due to a very high mortality rate among infected pregnant women and substantial morbidity, disability and costs associated with hepatitis E, concerted efforts are being made to develop an efficacious vaccine. Experimental vaccines, based on recombinant proteins derived from the capsid gene of HEV, have been shown efficacious in pre-clinical trials in macaques conferring cross-protection against various genotypes. Two vaccine candidates, the rHEV vaccine expressed in baculovirus and the HEV 239 vaccine, expressed in Escherichia coli, were successfully evaluated in Phase II/III trials. However, at this time no approved vaccine against hepatitis E is commercially available.
戊型肝炎病毒（HEV）可引起经肠道传播的急性肝炎大流行，也是在流行国家中引起大多数散发性急性肝炎的原因。由于感染孕妇的死亡率非常高，戊型肝炎还会导致大量发病、残疾和相关医疗费用，因此正在做出协同努力来开发有效的疫苗。基于 HEV 衣壳基因衍生的重组蛋白的实验性疫苗在猕猴中进行的临床前试验中已显示出有效，可对各种基因型提供交叉保护。两种疫苗候选物，即杆状病毒表达的 rHEV 疫苗和大肠杆菌表达的 HEV 239 疫苗，已在 II/III 期临床试验中成功评估。然而，目前尚无获得批准的戊型肝炎疫苗上市。
